Navigation Links
Generex Announces Publication of AE37 Prostate Cancer Vaccine Study
Date:8/6/2014

o prevent recurrence in patients who have had breast cancer.  That study has shown an encouraging trend toward preventing relapse, particularly in patients with low levels of HER2 expression and in triple negative patients.  The search for reliable biomarkers is a key priority in the emerging field of cancer immunotherapy.  The current study makes important contributions toward that aim while supplying compelling data for the further developmental of AE37.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
2. Generex Announces Selection of Antigen Express Technology for Keynote Presentation at 2014 TIDES Conference
3. Generex/Antigen Express Announce Database Lock of AE37 Breast Cancer Vaccine Trial
4. Generex Confirms Conference Call with Members of the Antigen Express Scientific Advisory Board
5. Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
6. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
7. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
8. Generex Announces Date of Annual Stockholders Meeting
9. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
10. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
11. Generex Secures Commitments for $3.6M Capital Raise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... HILL, N.C. , Sept. 16, 2014 ... experimental heart failure compound has been shown to be ... preclinical results demonstrate an alternative to intravenous infusions that ... HNO prodrugs. The data were presented yesterday at the ... Annual Scientific Meeting in Las Vegas ...
(Date:9/16/2014)... East Longmeadow, MA (PRWEB) September 16, 2014 ... the appointment of Brian Highley as CEO of CIRTEC. ... at this exciting point for the Company.” noted Brian ... and operational performance while sustaining strong organic growth over ... accelerate CIRTEC’s growth by continuing to improve and expand ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... September 16, 2014 Convoy Therapeutics, ... and effective products to treat patients directly at ... a proprietary SPACE™ Technology Platform announced today that ... will present at the White Hat Life Science ... Hyatt Regency Phoenix. In addition, interested individuals ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... 19, 2012 RayBiotech, Inc. today announced that it ... core facilities at academic and government research institutes in ... the partnership program, core diagnostics facilities will be able ... component of their current services offerings at no cost ...
... 19, 2012  New data presented today studied the ... nitric oxide (NO) to patients being evaluated for ... privately held, advanced development-stage technology company, announced that ... Right Heart Catheterization (RHC) in subjects being evaluated ...
... Childhood obesity is a widespread global epidemic ... (NAFLD) [2] is now the leading cause of liver ... Liver Congress™ 2012 furthers this concern by showing that childhood ... the most common form of liver cancer [3] - ...
Cached Biology Technology:RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 2Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 3Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 4
(Date:9/16/2014)... The fire is human-caused and is still under ... and is mostly being fueled by grass and timber. ... to higher humidity. Yesterday (8/15), firefighters made progress ... fireline on the West and North sides of the fire. ... 7 20-person Crews, 4 Hot Shot Crews, 1 large Type ...
(Date:9/16/2014)... -- Each tree species has its own bacterial identity. ... colleagues from other institutions who studied the genetic fingerprints ... a Panamanian island. , "This study demonstrates for the ... and with different ecological strategies possess very different microbial ... Kembel, a former postdoctoral researcher in the UO,s Institute ...
(Date:9/16/2014)... new school year, a new football season and another ... September, SpaceX,s Dragon spacecraft is scheduled to blast off ... part of the company,s fourth contracted mission to the ... third suite of research investigations sponsored by the Center ... the role of managing the U.S. National Laboratory on ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... Humans and animals are able to perceive even the ... channels play a crucial role in the mediation of ... membrane which are highly responsive to external signals. Mechanosensitive ... ions (electrically charged particles), to cross the cell membrane, ...
... oil and gas concessions threatens the megadiverse Peruvian Amazon. ... reach around 70% of the region, threatening biodiversity and ... from a pair of researchers from the Institut de ... Barcelona (UAB), and the Washington DC-based NGO Save America,s ...
... and THE HAGUE, The Netherlands -- Recognizing the ... relationship and become recognized research leaders in the ... security, Stevens Institute of Technology recently entered into ... A Memorandum of Understanding (MOU) between the university ...
Cached Biology News:MDC researchers link protein tether to touch perception 2A second hydrocarbon boom threatens the Peruvian Amazon 2A second hydrocarbon boom threatens the Peruvian Amazon 3Stevens and TNO to collaborate on maritime security 2
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
... against Nonmuscle Myosin II Heavy Chain ... in TBS + 0.03% Thimerosal) This ... SDVNETQPPQSE corresponding to the C-terminus of ... (MHC-B) This antibody is effective in ...
... reduced and non-reduced forms. It does not react ... XII. Factor XIII is a Beta-globulin found in ... XIII-A is the catalytic subunit and is a ... in plasma as an Alpha2Beta2 heterodimer (M.W. 320kDa); ...
... is a fully integrated system for fluorescent ... that deliver excellent quality microarray images. The ... microarray scanner that is based on patented ... rejection and spatial resolution. The DNAscope V ...
Biology Products: